Vaccines Market by Technology, Type, Disease, ROA, Competition - Global Forecast to 2031

1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regions Covered
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.3.4 Currency Considered
1.4 Stakeholders
1.5 Summary of Changes

2.1 Market Highlights and Key Insights
2.2 Key Market Participants: Mapping of Strategic Developments
2.3 Disruptive Trends in Vaccines Market
2.4 High-Growth Segments
2.5 Regional Snapshot: Market Size, Growth Rate, and Forecast

3.1 Vaccines Market Overview
3.2 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Type and Country, 2025
3.3 Vaccines Market (Excluding COVID-19 Vaccines): Geographic Growth Opportunities
3.4 Vaccines Market (Excluding COVID-19 Vaccines) Share, by Route of Administration, 2026 Vs 2031 (%)

4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Focus on Vaccine Development and Launches
4.2.1.2 Rising Prevalence of Infectious Diseases
4.2.1.3 Increasing Immunization Programs
4.2.1.4 Advancements in Vaccine Technology
4.2.1.5 Government Support and Funding for Vaccine Development
4.2.2 Restraints
4.2.2.1 High Cost of Vaccine Development
4.2.3 Opportunities
4.2.3.1 Rising Focus on Therapeutic Vaccines
4.2.3.2 Extensive R&D for Vaccines and Increased Investments in Clinical Trials
4.2.4 Challenges
4.2.4.1 Stringent Regulatory Processes
4.2.4.2 Product Recalls
4.3 Unmet Needs & White Spaces
4.4 Interconnected Markets & Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players

5.1 Porter's Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Competitive Rivalry
5.2 Macroeconomic Outlook
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Vaccines Industry
5.3 Value Chain Analysis
5.4 Pipeline Analysis
5.4.1 Vaccines Market: Clinical Trials, by Phase
5.4.2 Vaccines Market: Clinical Trials, by Disease Indication
5.4.3 Vaccines Market: Phase 2/3 Clinical Trials, by Company
5.5 Ecosystem Analysis
5.6 Pricing Analysis
5.6.1 Average Selling Price Trend, by Key Player, 2024-2026
5.6.2 Average Selling Price Trend, by Disease Indication, 2024-2026
5.6.3 Average Selling Price Trend, by Region, 2022-2024
5.7 Trade Analysis
5.7.1 Import Scenario (Hs Code 300220)
5.7.2 Export Scenario (Hs Code 300220)
5.8 Key Conferences and Events, 2026-2027
5.9 Trends/Disruptions Impacting Customers’ Business
5.10 Investment and Funding Scenario
5.10.1 Vc/Private Equity Investment Trends & Startup Landscape
5.11 Impact of 2025 US Tariffs - Vaccines Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact on Countries/Regions
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia-Pacific
5.11.5 Impact on End-Use Industries
5.11.5.1 Public Health & Government Bodies
5.11.5.2 Healthcare Providers & Institutions
5.12 Vaccine Procurement Data
5.12.1 Number of Vaccines Delivered by Unicef, 2024-2026
5.12.2 Who: Vaccine Purchase Database, 2022-2024
5.13 Vaccine Manufacturing Process
5.13.1 Overview
5.13.1.1 R&D and Process Development
5.13.1.2 Upstream Production (Antigen Generation)
5.13.1.3 Downstream Processing
5.13.1.4 Formulation & Fill-Finish
5.13.1.5 Quality Control & Regulatory Release
5.13.1.6 Packaging, Cold Chain, and Distribution
5.13.2 Manufacturing Models & Capacity Dynamics

6.1 Technology Analysis
6.1.1 Key Emerging Technologies
6.1.1.1 Recombinant Technology
6.1.1.2 Conjugation Technology
6.1.1.3 Viral Vector Technology
6.1.2 Complementary Technologies
6.1.2.1 Encapsulation & Delivery Technology
6.1.2.2 Automation & Control
6.1.2.3 AI & Machine Learning for Vaccine Design
6.1.3 Adjacent Technologies
6.1.3.1 Single-Use Technology
6.1.3.2 Cell Line Development
6.2 Technology/Product Roadmap
6.3 Patent Analysis
6.3.1 Top Applicants/Owners (Companies) for Vaccine Patents
6.4 Future Applications
6.5 Impact of AI/Gen AI - Vaccines Market
6.5.1 Best Practices in Vaccines Workflow
6.5.2 Case Studies of AI Implementation in Vaccines Market
6.5.3 Interconnected Adjacent Ecosystems & Impact on Market Players
6.5.4 Clients’ Readiness to Adopt Generative AI in Vaccines Market

7.1 Regional Regulations and Compliance
7.1.1 Regulatory Bodies, Government Agencies, and Other Organizations
7.1.2 Regulatory Framework
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia-Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 Regulatory Challenges in Vaccines Market
7.1.4 Industry Standards
7.2 Sustainability Initiatives
7.3 Impact of Regulatory Policies on Sustainability
7.4 Certifications, Labeling, and Eco-Standards

8.1 Decision-Making Process
8.2 Buyer Stakeholders & Buying Evaluation Criteria
8.2.1 Key Stakeholders in Buying Process
8.2.2 Key Buying Criteria, by End User
8.3 Adoption Barriers & Internal Challenges
8.4 Unmet Needs From Various End-Use Industries
8.5 Market Profitability

9.1 Introduction
9.2 Pneumococcal Disease
9.2.1 Expanding Adult Immunization Programs and Higher-Valency Vaccines to Drive Market
9.3 Influenza
9.3.1 Seasonal Immunization Programs and Expanding Adult Vaccination to Drive Market
9.4 Hpv
9.4.1 Expanding National Hpv Immunization Programs and Rising Adoption of Gender-Neutral Vaccination to Drive the Fastest-Growing Segment
9.5 Herpes Zoster
9.5.1 Rising Aging Population to Drive Demand for Herpes Zoster Vaccines
9.6 Combination Vaccines
9.6.1 Expanding National Immunization Programs and Growing Preference for Multi-Antigen Vaccines to Drive Market
9.7 Meningococcal Disease
9.7.1 Expanding Immunization Recommendations and Broader Serogroup Coverage to Support Market Growth
9.8 Rotavirus
9.8.1 Rising Infant Immunization Programs to Drive Rotavirus Market Growth
9.9 Rsv
9.9.1 Initial Vaccine Uptake and Expanding Immunization Recommendations Support Market Penetration
9.10 Dtp
9.10.1 Continued Routine Childhood Immunization and Booster Vaccination Programs to Support Market
9.11 Hepatitis
9.11.1 Expanding Hepatitis B Immunization and Global Elimination Initiatives to Support Market Growth
9.12 Varicella
9.12.1 Expanding Childhood Immunization Programs and Increasing Adoption of Varicella Vaccines to Support Market Growth
9.13 Mmr
9.13.1 Rising Measles Outbreaks and Immunization Recovery Efforts to Support Market Growth
9.14 Polio
9.14.1 Global Polio Eradication Initiatives and Continued Vaccination Campaigns to Sustain Market Demand
9.15 COVID-19
9.15.1 Shift From Pandemic-Driven Demand to Enduring High-Risk Population Vaccination, Resulting in Market Normalization
9.16 Other Disease Indications

10.1 Introduction
10.2 Vaccines Market (Excluding COVID-19 Vaccines), by Technology
10.2.1 Recombinant Vaccines
10.2.1.1 Broader Adult Immunization and Continued Recombinant Vaccine Launches to Drive Market
10.2.2 Conjugate Vaccines
10.2.2.1 Higher-Valency Pneumococcal Vaccines and Large Public Immunization Programs to Drive Market
10.2.3 Inactivated & Subunit Vaccines
10.2.3.1 Recurring Influenza Demand and Wider Access to Established Non-Live Vaccines to Support Market
10.2.4 Live Attenuated Vaccines
10.2.4.1 Durable Immune Protection and Convenient Oral or Nasal Administration to Support Market
10.2.5 Toxoid Vaccines
10.2.5.1 Routine Pediatric Boosters and Maternal Immunization Programs to Sustain Market
10.2.6 Other Vaccines
10.3 COVID-19 Vaccines Market, by Technology
10.3.1 Mrna Vaccines
10.3.1.1 Rapid Variant Adaptation and Continued Vaccination of High-Risk Populations to Drive Market
10.3.2 Viral Vector Vaccines
10.3.2.1 Withdrawal of First-Generation Products and Shift Toward Updated Vaccine Platforms to Accelerate Market Decline
10.3.3 Other COVID-19 Vaccines

11.1 Introduction
11.2 Multivalent Vaccines
11.2.1 Broader Serotype Coverage and Increasing Adoption of Combination Immunization Schedules to Drive Market
11.3 Monovalent Vaccines
11.3.1 Established Single-Disease Programs and Expanding Adult Immunization Indications to Support Market

12.1 Introduction
12.2 Intramuscular & Subcutaneous Administration
12.2.1 Ease of Absorption and Better Immune Response to Drive Adoption
12.3 Oral Administration
12.3.1 Needle-Free Delivery and High-Volume Disease-Control Campaigns to Support Market
12.4 Other Routes of Administration

13.1 Introduction
13.2 Adult Vaccines
13.2.1 Aging Populations, Broader Adult Indications, and Growing Life-Course Immunization to Drive Market
13.3 Pediatric Vaccines
13.3.1 Expanding Childhood Immunization Schedules and New Vaccine Introductions to Drive Market Growth

14.1 Introduction
14.2 North America
14.2.1 US
14.2.1.1 US to Dominate North American Market During Forecast Period
14.2.2 Canada
14.2.2.1 Expansion of Life-Course Immunization to Support Market Growth
14.3 Europe
14.3.1 Germany
14.3.1.1 Adult Immunization and Updated National Recommendations to Drive Market Growth
14.3.2 UK
14.3.2.1 Expansion of Adult and Maternal Immunization Programs to Support Market Growth
14.3.3 France
14.3.3.1 Favorable Government Initiatives for Mass Immunization to Drive Market
14.3.4 Italy
14.3.4.1 Higher Investments by Companies for Increased Production Capacities to Drive Market
14.3.5 Spain
14.3.5.1 Rising Investments in Vaccine Development by Private Organizations to Drive Market
14.3.6 Rest of Europe
14.4 Asia-Pacific
14.4.1 China
14.4.1.1 China to Hold Largest Share of APAC Vaccines Market
14.4.2 Japan
14.4.2.1 Aging Population and Gradual Expansion of Routine Vaccination to Drive Demand
14.4.3 India
14.4.3.1 Large Immunization Requirements and Manufacturing Leadership to Support Strong Growth
14.4.4 South Korea
14.4.4.1 Strong Government Strategies for Improved Vaccine Hubs to Drive Market
14.4.5 Rest of Asia-Pacific
14.5 Latin America
14.5.1 Brazil
14.5.1.1 Strong Public Procurement and Domestic Manufacturing to Drive Market
14.5.2 Mexico
14.5.2.1 Trained Workforce and Ethnically Varied Population Base for Clinical Trials to Propel Market Growth
14.5.3 Rest of Latin America
14.6 Middle East
14.6.1 Government-Led Localization and Expanding Adult and Travel Immunization to Support Market Growth
14.7 Africa
14.7.1 High Unmet Immunization Needs and Local Manufacturing Initiatives to Drive Market Expansion

15.1 Overview
15.2 Key Player Strategies/Right to Win
15.2.1 Overview of Strategies Adopted by Players in Vaccines Market
15.3 Revenue Analysis, 2021-2025
15.4 Market Share Analysis, 2025
15.5 Company Evaluation Matrix: Key Players, 2025
15.5.1 Stars
15.5.2 Emerging Leaders
15.5.3 Pervasive Players
15.5.4 Participants
15.5.5 Company Footprint: Key Players, 2025
15.5.5.1 Company Footprint
15.5.5.2 Region Footprint
15.5.5.3 Technology Footprint
15.5.5.4 Type Footprint
15.5.5.5 Route of Administration Footprint
15.6 Company Evaluation Matrix: Startups/SMEs, 2025
15.6.1 Progressive Companies
15.6.2 Responsive Companies
15.6.3 Dynamic Companies
15.6.4 Starting Blocks
15.6.5 Competitive Benchmarking: Startups/SMEs, 2025
15.6.5.1 Detailed List of Key Startups/SMEs
15.6.5.2 Competitive Benchmarking of Key Startups/SMEs
15.7 Company Valuation & Financial Metrics
15.7.1 Financial Metrics
15.7.2 Company Valuation
15.8 Product Comparison
15.8.1 Product Comparative Analysis
15.9 Competitive Scenario
15.9.1 Product Launches & Approvals
15.9.2 Deals
15.9.3 Expansions

16.1 Key Players
16.1.1 Pfizer Inc.
16.1.1.1 Business Overview
16.1.1.2 Products Offered
16.1.1.3 Recent Developments
16.1.1.3.1 Product Approvals
16.1.1.4 Analyst's View
16.1.1.4.1 Key Strengths
16.1.1.4.2 Strategic Choices
16.1.1.4.3 Weaknesses & Competitive Threats
16.1.2 Gsk PLC
16.1.2.1 Business Overview
16.1.2.2 Products Offered
16.1.2.3 Recent Developments
16.1.2.3.1 Product Launches & Approvals
16.1.2.3.2 Deals
16.1.2.3.3 Expansions
16.1.2.4 Analyst's View
16.1.2.4.1 Key Strengths
16.1.2.4.2 Strategic Choices
16.1.2.4.3 Weaknesses & Competitive Threats
16.1.3 Merck & Co. Inc.
16.1.3.1 Business Overview
16.1.3.2 Products Offered
16.1.3.3 Recent Developments
16.1.3.3.1 Product Approvals
16.1.3.3.2 Expansions
16.1.3.4 Analyst's View
16.1.3.4.1 Key Strengths
16.1.3.4.2 Strategic Choices
16.1.3.4.3 Weaknesses & Competitive Threats
16.1.4 Sanofi
16.1.4.1 Business Overview
16.1.4.2 Products Offered
16.1.4.3 Recent Developments
16.1.4.3.1 Product Approvals
16.1.4.3.2 Deals
16.1.4.3.3 Expansions
16.1.4.3.4 Other Developments
16.1.4.4 Analyst's View
16.1.4.4.1 Key Strengths
16.1.4.4.2 Strategic Choices
16.1.4.4.3 Weaknesses & Competitive Threats
16.1.5 Csl
16.1.5.1 Business Overview
16.1.5.2 Products Offered
16.1.5.3 Recent Developments
16.1.5.3.1 Product Approvals
16.1.5.3.2 Deals
16.1.5.3.3 Expansions
16.1.6 Emergent
16.1.6.1 Business Overview
16.1.6.2 Products Offered
16.1.6.3 Recent Developments
16.1.6.3.1 Product Approvals
16.1.6.3.2 Deals
16.1.6.3.3 Other Developments
16.1.7 Johnson & Johnson Services, Inc.
16.1.7.1 Business Overview
16.1.7.2 Products Offered
16.1.7.3 Recent Developments
16.1.7.3.1 Deals
16.1.8 Astrazeneca
16.1.8.1 Business Overview
16.1.8.2 Products Offered
16.1.8.3 Recent Developments
16.1.8.3.1 Deals
16.1.8.3.2 Expansions
16.1.9 Serum Institute of India Pvt. Ltd.
16.1.9.1 Business Overview
16.1.9.2 Products Offered
16.1.9.3 Recent Developments
16.1.9.3.1 Product Launches & Approvals
16.1.9.3.2 Deals
16.1.9.3.3 Expansions
16.1.10 Bavarian Nordic
16.1.10.1 Business Overview
16.1.10.2 Products Offered
16.1.10.3 Recent Developments
16.1.10.3.1 Product Approvals
16.1.10.3.2 Deals
16.1.10.3.3 Other Developments
16.1.11 Tanabe Pharma Corporation
16.1.11.1 Business Overview
16.1.11.2 Products Offered
16.1.11.3 Recent Developments
16.1.11.3.1 Product Launches & Approvals
16.1.11.3.2 Deals
16.1.12 Daiichi Sankyo Company, Limited
16.1.12.1 Business Overview
16.1.12.2 Products Offered
16.1.12.3 Recent Developments
16.1.12.3.1 Deals
16.1.13 Panacea Biotec
16.1.13.1 Business Overview
16.1.13.2 Products Offered
16.1.13.3 Recent Developments
16.1.13.3.1 Other Developments
16.1.14 Biological E. Limited
16.1.14.1 Business Overview
16.1.14.2 Products Offered
16.1.14.3 Recent Developments
16.1.14.3.1 Product Approvals
16.1.14.3.2 Deals
16.1.14.3.3 Other Developments
16.1.15 Bharat Biotech
16.1.15.1 Business Overview
16.1.15.2 Products Offered
16.1.15.3 Recent Developments
16.1.15.3.1 Product Launches & Approvals
16.1.15.3.2 Deals
16.1.16 Novavax
16.1.16.1 Business Overview
16.1.16.2 Products Offered
16.1.16.3 Recent Developments
16.1.16.3.1 Product Approvals
16.1.16.3.2 Deals
16.1.17 Inovio Pharmaceuticals
16.1.17.1 Business Overview
16.1.17.2 Products Offered
16.1.17.3 Recent Developments
16.1.17.3.1 Other Developments
16.2 Other Players
16.2.1 Sinovac
16.2.2 Incepta Pharmaceuticals Ltd.
16.2.3 Valneva SE
16.2.4 Eubiologics Co. Ltd.
16.2.5 Bio Farma
16.2.6 Microgen
16.2.7 Chongqing Zhifei Biological Products Co. Ltd.
16.2.8 Indian Immunologicals Limited

17.1 Research Data
17.1.1 Secondary Data
17.1.1.1 Key Secondary Sources
17.1.1.2 Key Data From Secondary Research
17.1.2 Primary Data
17.1.2.1 Key Primary Participants
17.1.2.2 Breakdown of Primary Interviews
17.1.2.3 Key Data From Primary Sources
17.2 Market Size Estimation
17.2.1 Global Vaccines Market Size Estimation, 2025
17.2.1.1 Approach 1: Company Revenue Analysis-Based Estimation (Bottom-Up Approach)
17.2.1.2 Approach 2: Primary Research
17.2.1.2.1 Key Industry Insights
17.2.1.3 Approach 3: Secondary Analysis
17.2.1.4 Approach 4: Bottom-Up Approach (Disease Indication-Based Analysis)
17.2.1.5 Approach 5: The Repository Analysis
17.2.2 Segmental Market Size Estimation (Top-Down Approach), 2025
17.3 Market Growth Rate Projections
17.4 Data Triangulation
17.5 Research Assumptions
17.6 Research Limitations & Risk Assessment

18.1 Discussion Guide
18.2 Knowledgestore: The Subscription Portal
18.3 Customization Options
18.4 Related Reports
18.5 Author Details

Table 1 Vaccines Market: Inclusions & Exclusions
Table 2 Vaccines Market: Impact Analysis of Market Dynamics
Table 3 Nih Funding for Vaccine Research, 2020-2025 (USD Million)
Table 4 Major Cost Drivers and Impact on Cost of Goods Sold (Cogs)
Table 5 Notable Cancer Vaccines in Clinical Trials
Table 6 Vaccines Market: Impact of Porter's Five Forces
Table 7 Vaccine Pipeline Products Under Phase 3 Clinical Trials for Rsv
Table 8 Vaccine Pipeline Products Under Phase 3 Clinical Trials for Cancer
Table 9 Vaccine Pipeline Products Under Phase 3 Clinical Trials for Influenza
Table 10 Key Pipeline Vaccines: Gsk PLC
Table 11 Key Pipeline Vaccines: Merck & Co. Inc.
Table 12 Key Pipeline Vaccines: Pfizer Inc.
Table 13 Key Pipeline Vaccines: Sanofi
Table 14 Vaccines Market: Role in Ecosystem
Table 15 Average Selling Price Trend of Pediatric Vaccines, by Key Player, 2024-2026 (USD)
Table 16 Average Selling Price Trend of Adult Vaccines, by Key Player, 2024-2026 (USD)
Table 17 Average Selling Price Trend of Vaccines, by Region, 2022-2024 (USD)
Table 18 Import Data for Hs Code 300220, 2021-2025 (USD Thousand)
Table 19 Import Data for Hs Code 300220, 2021-2025 (Tons)
Table 20 Export Data for Hs Code 300220, 2021-2025 (USD Thousand)
Table 21 Export Data for Hs Code 300220, 2021-2025 (Tons)
Table 22 Vaccines Market: Key Conferences and Events, 2026-2027
Table 23 US Adjusted Reciprocal Tariff Rates
Table 24 Number of Vaccines Delivered by Unicef, 2024-2026
Table 25 Who Vaccine Purchase Database, by Procurement Mechanism, 2022-2024
Table 26 Who Vaccine Purchase Database, by Manufacturer, 2022-2024
Table 27 Who Vaccine Purchase Database, by Indication, 2022-2024
Table 28 Who Vaccine Purchase Database, by Region, 2022-2024
Table 29 Vaccine Production Capacity, by Key Player, 2025
Table 30 Key Vaccine Manufacturing Capacity Expansions, 2025-2026
Table 31 Vaccines Market: Indicative List of Patents, 2026
Table 32 Case Studies of AI Implementation in Vaccines Market
Table 33 Client's Readiness to Adopt Generative AI in Vaccines
Table 34 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 35 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 36 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 37 Rest of the World: Regulatory Bodies, Government Agencies, and Other Organizations
Table 38 Influence of Stakeholders on Buying Process, by Vaccines
Table 39 Key Buying Criteria, by End User
Table 40 Vaccines Market, by Disease Indication, 2024-2031 (USD Million)
Table 41 List of Commercially Available Pneumococcal Disease Vaccines
Table 42 Pneumococcal Disease Vaccines Market, by Region, 2024-2031 (USD Million)
Table 43 North America: Pneumococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 44 Europe: Pneumococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 45 Asia-Pacific: Pneumococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 46 Latin America: Pneumococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 47 List of Commercially Available Influenza Vaccines
Table 48 Influenza Vaccines Market, by Region, 2024-2031 (USD Million)
Table 49 North America: Influenza Vaccines Market, by Country, 2024-2031 (USD Million)
Table 50 Europe: Influenza Vaccines Market, by Country, 2024-2031 (USD Million)
Table 51 Asia-Pacific: Influenza Vaccines Market, by Country, 2024-2031 (USD Million)
Table 52 Latin America: Influenza Vaccines Market, by Country, 2024-2031 (USD Million)
Table 53 List of Commercially Available Hpv Vaccines
Table 54 Hpv Vaccines Market, by Region, 2024-2031 (USD Million)
Table 55 North America: Hpv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 56 Europe: Hpv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 57 Asia-Pacific: Hpv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 58 Latin America: Hpv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 59 List of Commercially Available Herpes Zoster Vaccines
Table 60 Herpes Zoster Vaccines Market, by Region, 2024-2031 (USD Million)
Table 61 North America: Herpes Zoster Vaccines Market, by Country, 2024-2031 (USD Million)
Table 62 Europe: Herpes Zoster Vaccines Market, by Country, 2024-2031 (USD Million)
Table 63 Asia-Pacific: Herpes Zoster Vaccines Market, by Country, 2024-2031 (USD Million)
Table 64 Latin America: Herpes Zoster Vaccines Market, by Country, 2024-2031 (USD Million)
Table 65 List of Commercially Available Combination Vaccines
Table 66 Combination Vaccines Market, by Region, 2024-2031 (USD Million)
Table 67 North America: Combination Vaccines Market, by Country, 2024-2031 (USD Million)
Table 68 Europe: Combination Vaccines Market, by Country, 2024-2031 (USD Million)
Table 69 Asia-Pacific: Combination Vaccines Market, by Country, 2024-2031 (USD Million)
Table 70 Latin America: Combination Vaccines Market, by Country, 2024-2031 (USD Million)
Table 71 List of Commercially Available Meningococcal Disease Vaccines
Table 72 Meningococcal Disease Vaccines Market, by Region, 2024-2031 (USD Million)
Table 73 North America: Meningococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 74 Europe: Meningococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 75 Asia-Pacific: Meningococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 76 Latin America: Meningococcal Disease Vaccines Market, by Country, 2024-2031 (USD Million)
Table 77 List of Commercially Available Rotavirus Vaccines
Table 78 Rotavirus Vaccines Market, by Region, 2024-2031 (USD Million)
Table 79 North America: Rotavirus Vaccines Market, by Country, 2024-2031 (USD Million)
Table 80 Europe: Rotavirus Vaccines Market, by Country, 2024-2031 (USD Million)
Table 81 Asia-Pacific: Rotavirus Vaccines Market, by Country, 2024-2031 (USD Million)
Table 82 Latin America: Rotavirus Vaccines Market, by Country, 2024-2031 (USD Million)
Table 83 List of Commercially Available Rsv Vaccines
Table 84 Rsv Vaccines Market, by Region, 2024-2031 (USD Million)
Table 85 North America: Rsv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 86 Europe: Rsv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 87 Asia-Pacific: Rsv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 88 Latin America: Rsv Vaccines Market, by Country, 2024-2031 (USD Million)
Table 89 List of Commercially Available Dtp Vaccines
Table 90 Dtp Vaccines Market, by Region, 2024-2031 (USD Million)
Table 91 North America: Dtp Vaccines Market, by Country, 2024-2031 (USD Million)
Table 92 Europe: Dtp Vaccines Market, by Country, 2024-2031 (USD Million)
Table 93 Asia-Pacific: Dtp Vaccines Market, by Country, 2024-2031 (USD Million)
Table 94 Latin America: Dtp Vaccines Market, by Country, 2024-2031 (USD Million)
Table 95 List of Commercially Available Hepatitis Vaccines
Table 96 Hepatitis Vaccines Market, by Region, 2024-2031 (USD Million)
Table 97 North America: Hepatitis Vaccines Market, by Country, 2024-2031 (USD Million)
Table 98 Europe: Hepatitis Vaccines Market, by Country, 2024-2031 (USD Million)
Table 99 Asia-Pacific: Hepatitis Vaccines Market, by Country, 2024-2031 (USD Million)
Table 100 Latin America: Hepatitis Vaccines Market, by Country, 2024-2031 (USD Million)
Table 101 List of Commercially Available Varicella Vaccines
Table 102 Varicella Vaccines Market, by Region, 2024-2031 (USD Million)
Table 103 North America: Varicella Vaccines Market, by Country, 2024-2031 (USD Million)
Table 104 Europe: Varicella Vaccines Market, by Country, 2024-2031 (USD Million)
Table 105 Asia-Pacific: Varicella Vaccines Market, by Country, 2024-2031 (USD Million)
Table 106 Latin America: Varicella Vaccines Market, by Country, 2024-2031 (USD Million)
Table 107 Top 10 Countries With Measles Outbreaks, January 2025-July 2025
Table 108 List of Commercially Available Mmr Vaccines
Table 109 Mmr Vaccines Market, by Region, 2024-2031 (USD Million)
Table 110 North America: Mmr Vaccines Market, by Country, 2024-2031 (USD Million)
Table 111 Europe: Mmr Vaccines Market, by Country, 2024-2031 (USD Million)
Table 112 Asia-Pacific: Mmr Vaccines Market, by Country, 2024-2031 (USD Million)
Table 113 Latin America: Mmr Vaccines Market, by Country, 2024-2031 (USD Million)
Table 114 Polio Vaccines Market, by Region, 2024-2031 (USD Million)
Table 115 North America: Polio Vaccines Market, by Country, 2024-2031 (USD Million)
Table 116 Europe: Polio Vaccines Market, by Country, 2024-2031 (USD Million)
Table 117 Asia-Pacific: Polio Vaccines Market, by Country, 2024-2031 (USD Million)
Table 118 Latin America: Polio Vaccines Market, by Country, 2024-2031 (USD Million)
Table 119 COVID-19 Vaccines Market, by Region, 2024-2031 (USD Million)
Table 120 North America: COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 121 Europe: COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 122 Asia-Pacific: COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 123 Latin America: COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 124 List of Commercially Available Vaccines for Other Disease Indications
Table 125 Vaccines Market for Other Disease Indications, by Region, 2024-2031 (USD Million)
Table 126 North America: Vaccines Market for Other Disease Indications, by Country, 2024-2031 (USD Million)
Table 127 Europe: Vaccines Market for Other Disease Indications, by Country, 2024-2031 (USD Million)
Table 128 Asia-Pacific: Vaccines Market for Other Disease Indications, by Country, 2024-2031 (USD Million)
Table 129 Latin America: Vaccines Market for Other Disease Indications, by Country, 2024-2031 (USD Million)
Table 130 Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 131 Examples of Recombinant Vaccines
Table 132 Recombinant Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 133 North America: Recombinant Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 134 Europe: Recombinant Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 135 Asia-Pacific: Recombinant Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 136 Latin America: Recombinant Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 137 Examples of Conjugate Vaccines
Table 138 Conjugate Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 139 North America: Conjugate Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 140 Europe: Conjugate Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 141 Asia-Pacific: Conjugate Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 142 Latin America: Conjugate Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 143 Examples of Inactivated & Subunit Vaccines
Table 144 Inactivated & Subunit Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 145 North America: Inactivated & Subunit Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 146 Europe: Inactivated & Subunit Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 147 Asia-Pacific: Inactivated & Subunit Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 148 Latin America: Inactivated & Subunit Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 149 Examples of Live Attenuated Vaccines
Table 150 Live Attenuated Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 151 North America: Live Attenuated Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 152 Europe: Live Attenuated Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 153 Asia-Pacific: Live Attenuated Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 154 Latin America: Live Attenuated Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 155 Examples of Toxoid Vaccines
Table 156 Toxoid Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 157 North America: Toxoid Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 158 Europe: Toxoid Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 159 Asia-Pacific: Toxoid Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 160 Latin America: Toxoid Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 161 Other Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 162 North America: Other Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 163 Europe: Other Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 164 Asia-Pacific: Other Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 165 Latin America: Other Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 166 COVID-19 Vaccines Market, by Technology, 2024-2031 (USD Million)
Table 167 Mrna COVID-19 Vaccines Market, by Region, 2024-2031 (USD Million)
Table 168 North America: Mrna COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 169 Europe: Mrna COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 170 Asia-Pacific: Mrna COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 171 Latin America: Mrna COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 172 Viral Vector COVID-19 Vaccines Market, by Region, 2024-2031 (USD Million)
Table 173 North America: Viral Vector COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 174 Europe: Viral Vector COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 175 Asia-Pacific: Viral Vector COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 176 Latin America: Viral Vector COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 177 Other COVID-19 Vaccines Market, by Region, 2024-2031 (USD Million)
Table 178 North America: Other COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 179 Europe: Other COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 180 Asia-Pacific: Other COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 181 Latin America: Other COVID-19 Vaccines Market, by Country, 2024-2031 (USD Million)
Table 182 Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 183 Examples of Multivalent Vaccines
Table 184 Multivalent Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 185 North America: Multivalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 186 Europe: Multivalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 187 Asia-Pacific: Multivalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 188 Latin America: Multivalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 189 Examples of Monovalent Vaccines
Table 190 Monovalent Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 191 North America: Monovalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 192 Europe: Monovalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 193 Asia-Pacific: Monovalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 194 Latin America: Monovalent Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 195 Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 196 Advantages and Disadvantages of Intramuscular & Subcutaneous Administration
Table 197 Vaccines Market for Intramuscular & Subcutaneous Administration (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 198 North America: Vaccines Market for Intramuscular & Subcutaneous Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 199 Europe: Vaccines Market for Intramuscular & Subcutaneous Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 200 Asia-Pacific: Vaccines Market for Intramuscular & Subcutaneous Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 201 Latin America: Vaccines Market for Intramuscular & Subcutaneous Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 202 Vaccines Market for Oral Administration (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 203 North America: Vaccines Market for Oral Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 204 Europe: Vaccines Market for Oral Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 205 Asia-Pacific: Vaccines Market for Oral Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 206 Latin America: Vaccines Market for Oral Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 207 Vaccines Market for Other Routes of Administration (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 208 North America: Vaccines Market for Other Routes of Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 209 Europe: Vaccines Market for Other Routes of Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 210 Asia-Pacific: Vaccines Market for Other Routes of Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 211 Latin America: Vaccines Market for Other Routes of Administration (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 212 Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 213 Adult Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 214 North America: Adult Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 215 Europe: Adult Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 216 Asia-Pacific: Adult Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 217 Latin America: Adult Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 218 Pediatric Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 219 North America: Pediatric Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 220 Europe: Pediatric Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 221 Asia-Pacific: Pediatric Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 222 Latin America: Pediatric Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 223 Vaccines Market (Excluding COVID-19 Vaccines), by Region, 2024-2031 (USD Million)
Table 224 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 225 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 226 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 227 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 228 North America: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 229 North America: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 230 US: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 231 US: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 232 US: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 233 US: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 234 US: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 235 Canada: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 236 Canada: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 237 Canada: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 238 Canada: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 239 Canada: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 240 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 241 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 242 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 243 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 244 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 245 Europe: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 246 Germany: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 247 Germany: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 248 Germany: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 249 Germany: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 250 Germany: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 251 UK: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 252 UK: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 253 UK: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 254 UK: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 255 UK: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 256 France: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 257 France: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 258 France: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 259 France: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 260 France: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 261 Italy: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 262 Italy: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 263 Italy: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 264 Italy: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 265 Italy: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 266 Spain: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 267 Spain: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 268 Spain: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 269 Spain: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 270 Spain: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 271 Rest of Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 272 Rest of Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 273 Rest of Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 274 Rest of Europe: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 275 Rest of Europe: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 276 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 277 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 278 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 279 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 280 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 281 Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 282 China: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 283 China: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 284 China: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 285 China: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 286 China: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 287 Japan: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 288 Japan: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 289 Japan: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 290 Japan: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 291 Japan: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 292 India: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 293 India: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 294 India: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 295 India: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 296 India: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 297 South Korea: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 298 South Korea: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 299 South Korea: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 300 South Korea: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 301 South Korea: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 302 Rest of Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 303 Rest of Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 304 Rest of Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 305 Rest of Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 306 Rest of Asia-Pacific: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 307 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Country, 2024-2031 (USD Million)
Table 308 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 309 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 310 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 311 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 312 Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 313 Brazil: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 314 Brazil: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 315 Brazil: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 316 Brazil: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 317 Brazil: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 318 Mexico: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 319 Mexico: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 320 Mexico: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 321 Mexico: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 322 Mexico: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 323 Rest of Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 324 Rest of Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 325 Rest of Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 326 Rest of Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 327 Rest of Latin America: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 328 Middle East: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 329 Middle East: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 330 Middle East: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 331 Middle East: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 332 Middle East: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 333 Africa: Vaccines Market (Excluding COVID-19 Vaccines), by Technology, 2024-2031 (USD Million)
Table 334 Africa: Vaccines Market (Excluding COVID-19 Vaccines), by Type, 2024-2031 (USD Million)
Table 335 Africa: Vaccines Market (Excluding COVID-19 Vaccines), by Disease Indication, 2024-2031 (USD Million)
Table 336 Africa: Vaccines Market (Excluding COVID-19 Vaccines), by Route of Administration, 2024-2031 (USD Million)
Table 337 Africa: Vaccines Market (Excluding COVID-19 Vaccines), by End User, 2024-2031 (USD Million)
Table 338 Overview of Strategies Adopted by Key Players in Vaccines Market, January 2023-July 2025
Table 339 Vaccines Market: Degree of Competition
Table 340 Vaccines Market: Region Footprint
Table 341 Vaccines Market: Technology Footprint
Table 342 Vaccines Market: Type Footprint
Table 343 Vaccines Market: Route of Administration Footprint
Table 344 Vaccines Market: Detailed List of Key Startups/SMEs
Table 345 Vaccines Market: Competitive Benchmarking of Key Startups/SMEs
Table 346 Vaccines Market: Product Launches & Approvals, January 2023-July 2026
Table 347 Vaccines Market: Deals, January 2023-July 2026
Table 348 Vaccines Market: Expansions, January 2023-July 2026
Table 349 Pfizer Inc.: Company Overview
Table 350 Pfizer Inc.: Products Offered
Table 351 Pfizer Inc.: Product Approvals, January 2023-July 2026
Table 352 Gsk PLC: Company Overview
Table 353 Gsk PLC: Products Offered
Table 354 Gsk PLC: Product Launches & Approvals, January 2023-July 2026
Table 355 Gsk PLC: Deals, January 2023-July 2026
Table 356 Gsk PLC: Expansions, January 2023-July 2026
Table 357 Merck & Co. Inc.: Company Overview
Table 358 Merck & Co. Inc.: Products Offered
Table 359 Merck & Co. Inc.: Product Approvals, January 2023-July 2026
Table 360 Merck & Co. Inc.: Expansions, January 2023-July 2026
Table 361 Sanofi: Company Overview
Table 362 Sanofi: Products Offered
Table 363 Sanofi: Product Approvals, January 2023-July 2026
Table 364 Sanofi: Deals, January 2023-July 2026
Table 365 Sanofi: Expansions, January 2023-July 2026
Table 366 Sanofi: Other Developments, January 2023-July 2026
Table 367 Csl: Company Overview
Table 368 Csl: Products Offered
Table 369 Csl: Product Approvals, January 2023-July 2026
Table 370 Csl: Deals, January 2023-July 2026
Table 371 Csl: Expansions, January 2023-July 2026
Table 372 Emergent: Company Overview
Table 373 Emergent: Products Offered
Table 374 Emergent: Product Approvals, January 2023-July 2026
Table 375 Emergent: Deals, January 2023-July 2026
Table 376 Emergent: Other Developments, January 2023-July 2026
Table 377 Johnson & Johnson Services, Inc.: Company Overview
Table 378 Johnson & Johnson Services, Inc.: Products Offered
Table 379 Johnson & Johnson Services, Inc.: Deals, January 2023-July 2026
Table 380 Astrazeneca: Company Overview
Table 381 Astrazeneca: Products Offered
Table 382 Astrazeneca: Deals, January 2023-July 2026
Table 383 Astrazeneca: Expansions, January 2023-July 2026
Table 384 Serum Institute of India Pvt. Ltd.: Company Overview
Table 385 Serum Institute of India Pvt. Ltd.: Products Offered (Supplied Overseas)
Table 386 Serum Institute of India Pvt. Ltd.: Products Offered (Supplied in India)
Table 387 Serum Institute of India Pvt. Ltd.: Products Launches & Approvals, January 2023-July 2026
Table 388 Serum Institute of India Pvt. Ltd.: Deals, January 2023-July 2026
Table 389 Serum Institute of India Pvt. Ltd.: Expansions, January 2023-July 2026
Table 390 Bavarian Nordic: Company Overview
Table 391 Bavarian Nordic: Products Offered
Table 392 Bavarian Nordic: Product Approvals, January 2023-July 2026
Table 393 Bavarian Nordic: Deals, January 2023-July 2026
Table 394 Bavarian Nordic: Other Developments, January 2023-July 2026
Table 395 Tanabe Pharma Corporation: Company Overview
Table 396 Tanabe Pharma Corporation: Products Offered
Table 397 Tanabe Pharma Corporation: Product Launches & Approvals, January 2023-July 2026
Table 398 Tanabe Pharma Corporation: Deals, January 2023-July 2026
Table 399 Daiichi Sankyo Company, Limited: Company Overview
Table 400 Daiichi Sankyo Company, Limited: Products Offered
Table 401 Daiichi Sankyo Company, Limited: Deals, January 2023-July 2026
Table 402 Panacea Biotec: Company Overview
Table 403 Panacea Biotec: Products Offered
Table 404 Panacea Biotec: Other Developments, January 2023-July 2026
Table 405 Biological E. Limited: Company Overview
Table 406 Biological E. Limited: Products Offered (Indian Market)
Table 407 Biological E. Limited: Products Offered (International Market)
Table 408 Biological E. Limited: Product Approvals, January 2023-July 2026
Table 409 Biological E. Limited: Deals, January 2023-July 2026
Table 410 Biological E. Limited: Other Developments, January 2023-July 2026
Table 411 Bharat Biotech: Company Overview
Table 412 Bharat Biotech: Products Offered
Table 413 Bharat Biotech: Product Launches & Approvals, January 2023-July 2026
Table 414 Bharat Biotech: Deals, January 2023-July 2026
Table 415 Novavax: Company Overview
Table 416 Novavax: Products Offered
Table 417 Novavax: Product Approvals, January 2023-July 2026
Table 418 Novavax: Deals, January 2023-July 2026
Table 419 Inovio Pharmaceuticals: Company Overview
Table 420 Inovio Pharmaceuticals: Products Offered
Table 421 Inovio Pharmaceuticals: Other Developments, January 2023-July 2026
Table 422 Sinovac: Company Overview
Table 423 Incepta Pharmaceuticals Ltd.: Company Overview
Table 424 Valneva SE: Company Overview
Table 425 Eubiologics Co. Ltd.: Company Overview
Table 426 Bio Farma: Company Overview
Table 427 Microgen: Company Overview
Table 428 Chongqing Zhifei Biological Products Co. Ltd.: Company Overview
Table 429 Indian Immunologicals Limited: Company Overview
Table 430 Impact Analysis of Supply-Side and Demand-Side Factors
Table 431 Vaccines Market: Risk Assessment

Figure 1 Vaccines Market Segmentation & Regions Covered
Figure 2 Market Scenario
Figure 3 Global Vaccines Market (Including COVID-19 Vaccines), 2024-2031
Figure 4 Major Strategies Adopted by Key Players in Vaccines Market, 2023-2026
Figure 5 Disruptions Influencing Growth of Vaccines Market
Figure 6 High-Growth Segments in Vaccines Market (Excluding COVID-19 Vaccines), 2026-2031
Figure 7 Asia-Pacific to Register Highest CAGR in Vaccines Market (Excluding COVID-19 Vaccines), in Terms of Value, During Forecast Period
Figure 8 Focus on Vaccine Development and Launches to Drive Market Growth
Figure 9 US and Multivalent Vaccines Accounted for the Largest Share of the Vaccines Market in North America in 2025
Figure 10 Asia-Pacific Is Likely to Be Fastest-Growing Market During 2026-2031
Figure 11 Intramuscular and Subcutaneous Route to Dominate Market During Forecast Period
Figure 12 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges
Figure 13 US: Novel Influenza A Virus Cases, by Season (2010-2011 to 2025-2026 Season)
Figure 14 Manufacturing-Related Parameters Included in Cost Model
Figure 15 US: Estimated Number of New Cancer Cases and Deaths by Site, 2025
Figure 16 Vaccines Market: Porter's Five Forces Analysis
Figure 17 Global GDP Growth, 2020-2030
Figure 18 Vaccines Market: Value Chain Analysis
Figure 19 Vaccines Market: Clinical Trials, by Phase
Figure 20 Vaccines Market: Clinical Trials, by Disease Indication
Figure 21 Vaccines Market Ecosystem
Figure 22 Average Selling Price Trend of Vaccines, by Disease Indication, 2024-2026 (USD)
Figure 23 Revenue Shift and New Revenue Pockets for Players in Vaccines Market
Figure 24 Vaccines Market: Pharmaceutical M&A Deal Activity, Number, and Aggregate Total Value, 2021-2025
Figure 25 Top Applicants/Owners (Companies) for Vaccine Patents, 2015-2025
Figure 26 Impact of AI/Gen AI on Vaccines Market
Figure 27 Influence of Stakeholders on Buying Process of Vaccines
Figure 28 Key Buying Criteria, by End User
Figure 29 North America: Vaccines Market Snapshot (Excluding COVID-19 Vaccines)
Figure 30 Asia-Pacific: Vaccines Market Snapshot (Excluding COVID-19 Vaccines)
Figure 31 Revenue Analysis of Key Players in Vaccines Market, 2021-2025 (USD Billion)
Figure 32 Market Share Analysis of Key Players in Vaccines Market, 2025
Figure 33 Vaccines Market: Company Evaluation Matrix (Key Players), 2025
Figure 34 Vaccines Market: Company Footprint
Figure 35 Vaccines Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 36 Ev/EBITDA of Key Vendors
Figure 37 Year-to-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors
Figure 38 Vaccines Market: Product Comparative Analysis
Figure 39 Pfizer Inc.: Company Snapshot (2025)
Figure 40 Gsk PLC: Company Snapshot (2025)
Figure 41 Merck & Co. Inc.: Company Snapshot (2025)
Figure 42 Sanofi: Company Snapshot (2025)
Figure 43 Csl: Company Snapshot (2025)
Figure 44 Emergent: Company Snapshot (2025)
Figure 45 Johnson & Johnson Services, Inc.: Company Snapshot (2025)
Figure 46 Astrazeneca: Company Snapshot (2025)
Figure 47 Bavarian Nordic: Company Snapshot (2025)
Figure 48 Daiichi Sankyo Company, Limited: Company Snapshot (2025)
Figure 49 Panacea Biotec: Company Snapshot (2024)
Figure 50 Novavax: Company Snapshot (2025)
Figure 51 Inovio Pharmaceuticals: Company Snapshot (2025)
Figure 52 Vaccines Market: Research Design
Figure 53 Vaccines Market: Breakdown of Primaries
Figure 54 Global Vaccines Market Size Estimation (Supply-Side Analysis), 2025
Figure 55 Global Vaccines Market: Company Revenue Analysis (Bottom-Up Approach), 2025
Figure 56 Illustrative Example of Pfizer Inc.: Revenue Analysis, 2025
Figure 57 Vaccines Market: Insights From Primaries
Figure 58 Illustrative Example of Influenza Vaccines: Company Revenue Analysis (Bottom-Up Approach), 2025
Figure 59 Segmental Market Size Estimation: Top-Down Approach
Figure 60 Vaccines Market: CAGR Projections
Figure 61 Vaccines Market: Data Triangulation